Lixin Li
Central Michigan University,USA
Title: Fat fight against fat, a potenital medication in treating obesity
Biography
Biography: Lixin Li
Abstract
rnObesity is a risk factor for many diseases, including type 2 diabetes. Glucagon like peptide -1 (GLP-1) and analogue are approved by FDA in treating type 2 diabets and has been reported having weight lowering effect in type 2 diabetes patients. Howerver, the underlying mechanisms has not been studied. We aimed to determine the contribution of brown adipose tissue (BAT) thermogenesis to the weight lowering effect induced by liraglutide, a full agonist of the GLP-1 receptor.rn rnMice were fed with either chow diet or high fat high sucrose diet (HFHSD), liraglutide or saline were injected daily for five weeks. Liraglutide significantly attenuated the weight gain along with attenuated epididymal fat mass compare with saline control group. Brown fat specific genes, uncoupling protein-1, were induced in white fat tissue (WAT) after liraglutide treatment, Transcription factor, PR domain–containing protein-16 (PRDM16) binds and coregulates C/EBPα, peroxisome proliferator-activated receptor gamma -α (PPAR-α) during brown fat differentiation, liraglutide significantly induced both genes. Peroxisome proliferator–activated receptor -coactivator-1-α( PGC-1 α), which involved in regulating mitochondrial biogenesis, oxidative metabolism, was also upregulated by liraglutide. In addiction Liraglutide reduced HFHSD induced elevation of BAX-2 ,BCL-2 and Caspases-3 gene expression in fat tissue, which indicated it reduced inflammation induced by obesity. rnrnOur results demonstrated the ability of liraglutide to reduce BW and adiposity, this protective effect on diet induced obesity may act through induction of beige fat (browning in WAT) which lead to elevated energy expenditure. Liraglutide is a potential therapy for obesity and obesity related metabolic disorders.rn